Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Zura Bio Limited - Class A Ordinary shares (NQ: ZURA )

3.490 -0.010 (-0.29%)
Streaming Delayed Price Updated: 10:55 AM EDT, Jul 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 60,155
Open 3.440
Bid (Size) 3.460 (4)
Ask (Size) 3.510 (6)
Prev. Close 3.500
Today's Range 3.420 - 3.615
52wk Range 2.000 - 7.400
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Zura Bio Commences Warrant Exchange Offer and Consent Solicitation
From Zura Bio Limited
Via Business Wire
The 3 Most Undervalued Biotech Stocks to Buy in July 2024
There’s always a strong case for undervalued biotech stocks especially with newer innovation and demand for better treatment. 
Via InvestorPlace

Performance

YTD
-19.77%
-19.77%
1 Month
-6.43%
-6.43%
3 Month
+11.50%
+11.50%
6 Month
-9.11%
-9.11%
1 Year
-44.95%
-44.95%

More News

Read More
Zura Bio Presents Data for the Tibulizumab (ZB-106) Program at EULAR 2024
From Zura Bio Limited
Via Business Wire
ZURA Stock Earnings: Zura Bio Beats EPS for Q2 2024
Via InvestorPlace
Zura Bio Forms Scientific Advisory Board with Prominent Specialists in Rheumatology, Dermatology, and Immunology
From Zura Bio Limited
Via Business Wire
Zura Bio to Present Data Exploring the Expanded Potential of Tibulizumab (ZB-106) into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024
From Zura Bio Limited
Via Business Wire
Zura Bio Announces Participation in June Investor Conferences
From Zura Bio Limited
Via Business Wire
3 Penny Stocks to Buy Now: May 2024
Via InvestorPlace
Zura Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
From Zura Bio Limited
Via Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Zura Bio Announces Oversubscribed $112.5 Million Private Placement
From Zura Bio
Via Business Wire
Zura Bio Announces Robert Lisicki as CEO and Director
From Zura Bio Limited
Via Business Wire
ZURA Stock Earnings: Zura Bio Misses EPS for Q4 2023
Via InvestorPlace
Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer
From Zura Bio Limited
Via Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Zura Bio Announces Participation at March Conferences
From Zura Bio Limited
Via Business Wire
Zura Bio Announces Participation at February Investor Conferences
From Zura Bio Limited
Via Business Wire
Zura Bio Continues to Strengthen Leadership with Appointment of Robert Lisicki as President and Kiran Nistala as CMO
From Zura Bio Limited
Via Business Wire
Zura Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Dermatology Summit
From Zura Bio Limited
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Zura Bio Announces Two Immunology Abstracts Presented at the World Allergy Congress in Bangkok
From Zura Bio Limited
Via Business Wire
Zura Bio Appoints Arnout Ploos van Amstel to its Board of Directors
From Zura Bio Limited
Via Business Wire
Zura Bio Reports Third Quarter 2023 Financial Results and Recent Business Highlights
From Zura Bio Limited
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For October 10, 2023
Via Benzinga
Zura Bio Enters into Sponsored Research Agreement with Benaroya Research Institute
From Zura Bio Limited
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.